The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue for the rest of the year.
Posted inBusiness
Sales of Biogen’s costly new Alzheimer’s drug fall far short of expectations.
